Antiretroviral Therapies in Women after Single-Dose Nevirapine Exposure
Author(s) -
Shahin Lockman,
Michael D. Hughes,
James McIntyre,
Yu Zheng,
Tsungai Chipato,
Francesca Conradie,
Fred Sawe,
Aida Asmelash,
Mina C. Hosseinipour,
Lerato Mohapi,
Jeffrey S. A. Stringer,
Rosie Mngqibisa,
Abraham Siika,
Daniel Atwine,
James Hakim,
David R. Shaffer,
Cecilia Kanyama,
Kara WoolsKaloustian,
Robert A. Salata,
Evelyn Hogg,
Beverly AlstonSmith,
Ann Walawander,
E. Purcelle-Smith,
S. Eshleman,
James F. Rooney,
Sharul Kamal Abdul Rahim,
John W. Mellors,
Robert T. Schooley,
Judith S. Currier
Publication year - 2010
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa0906626
Subject(s) - nevirapine , lopinavir , medicine , lopinavir/ritonavir , ritonavir , emtricitabine , virology , oncology , pharmacology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy
Peripartum administration of single-dose nevirapine reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) but selects for nevirapine-resistant virus.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom